Prescribe BRENZAVVY to Marley Drug
Marley Drug is in all EMRs. Send the prescription to Marley Drug and we'll take it from there.
Questions? Call us at 800-810-7790
BRENZAVVY® (bexagliflozin) tablets
Help Your Patients Take Control of Their Diabetes
Please refer to Prescribing Information or Important Safety Information below.
Meet BRENZAVVY
BRENZAVVY is an SGLT2 inhibitor backed by 23 studies involving over 5,000 people.
Better A1C: Lowers your average blood sugar (A1C). It works alone, with metformin, or added to insulin or other diabetes meds.
Daily blood sugar: Cuts fasting blood glucose levels; real control you can feel.
Kidney protection: First SGLT2 shown to help people with type 2 diabetes and moderate kidney issues (stage 3).
Stays effective long-term: Keeps lowering A1C for up to 3 years, with a low risk of hypoglycemia.
Finally - An Affordable SGLT2 Inhibitor
SGLT2 inhibitors are prescribed to millions of Americans suffering from heart disease, diabetes, or kidney dysfunction. Regrettably, the high retail price of over $500 for 30 tablets places these life-saving medications out of reach for many.
BRENZAVVY: Just $69 per Month
Brenzavvy is available through Marley Drug thanks to a partnership with the manufacturer. The manufacturer and Marley Drug share the goal of providing broader access to drugs at a low cost. Through this agreement we can offer this medication at a much lower price than other medications in its class by bypassing wholesalers and insurance middlemen (which contribute to the high cost of medications). Because of this, Brenzavvy is not available at local pharmacies.
Accessing BRENZAVVY at $69 per month* is hassle-free, without the need for insurance. We're able to offer this remarkable price through our partnership with TheracosBio, the manufacturer.
No insurance required
Nationwide free shipping
Available to all patients*
*With a valid prescription.
Hear from our Customers
We are using BRENZAVVY because of the strong data available regarding SGLT2 therapy and diabetic patients. The availability of an SGLT2 in an affordable formulation can be life-changing. Providing these ...Read MoreDr. Morgan
As I get older I keep struggling with blood sugar slowly creeping up and even with diet and exercise was averaging around 145. I found BRENZAVVY which was priced at $69 per month. Talked to my doctor ...Read MorePaul P.
I found the technician, Terri, to be one of the most helpful people that I have ever experienced. She went far and beyond in getting the prescription correctly written and followed up with both the doctor ...Read MoreVincent F.
As a senior citizens with type 2 diabetes I was researching for new affordable medication options - and I found BRENZAVVY. After 30 days I lost 6lbs and lowered my HbA1C. The major players such as JARDIANCE ...Read MoreBill H.
After not being able to afford JARDIANCE® I asked my doctor about BRENZAVVY. After receiving my prescription with just 1 dose my blood sugar dropped to acceptable levels and mind you I have been on the ...Read MoreMark G.
Stock photos are used to represent actual testimonials of Marley Drug customers.
How to Prescribe BRENZAVVY to Marley Drug
We Call Your Patient
Once we receive the prescription, we'll call your patient to verify their medical history and information.
Home Delivery
Once payment is received, we ship medications the same day. Average delivery time is 2 business days.
IMPORTANT SAFETY INFORMATION FOR BRENZAVVY (BEXAGLIFLOZIN) TABLETS
Indication: BRENZAVVYâ (bexagliflozin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
BRENZAVVY is not recommended for patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients.
Contraindications
Prior hypersensitivity to BRENZAVVY.
Warnings and Precautions
Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis
BRENZAVVY increases the risk of life-threatening ketoacidosis in patients with type 1 diabetes. Type 2 diabetes and pancreatic disorders are also risk factors for ketoacidosis and fatal events of ketoacidosis have been reported in patients with type 2 diabetes using SGLT2 inhibitors. Assess patients who present with signs and symptoms of metabolic ketoacidosis, regardless of blood glucose levels. If suspected, discontinue BRENZAVVY, evaluate and treat promptly. Patients on BRENZAVVY may require monitoring and temporary discontinuation in clinical situations known to predispose to ketoacidosis.
Lower Limb Amputation
Lower limb amputations have been observed in patients treated with BRENZAVVY in a study of patients with type 2 diabetes who had either established cardiovascular disease (CVD) or were at risk for CVD. Of the 23 BRENZAVVY-treated patients who had amputations, 15 were amputations of the toe and midfoot and 8 were amputations above and below the knee. Some patients had multiple amputations. The risk of amputation was highest in patients with a baseline history of prior amputation, peripheral vascular disease, and neuropathy.
Volume Depletion
BRENZAVVY can cause intravascular volume contraction which may sometimes manifest as symptomatic hypotension or acute transient changes in creatinine. Acute kidney injury requiring hospitalization and dialysis has been reported in patients with type 2 diabetes receiving SGLT2 inhibitors. Before initiating, assess volume status and renal function in patients with impaired renal function (eGFR less than 60 mL/min/1.73 m2), elderly patients or patients on diuretics, patients with low systolic blood pressure, or patients on loop diuretics. In patients with volume depletion, correct this condition. After initiating, monitor for signs and symptoms of volume depletion and renal function.
Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene), and Genital Mycotic Infections
BRENZAVVY increases urinary glucose excretion and is associated with a higher risk of genitourinary infections, including UTIs and genital mycotic infections, in both male and female patients. Serious complications such as urosepsis, pyelonephritis, and rare cases of Fournier’s gangrene have been reported with SGLT2 inhibitors and may require hospitalization or surgical intervention. Patients with a history of chronic or recurrent genitourinary infections are at an increased risk; therefore, they should be monitored closely and treated promptly for any infections. Evaluate urgently for necrotizing fasciitis in patients with genital or perineal pain, erythema, swelling, fever, or malaise, and discontinue BRENZAVVY if suspected.
Hypoglycemia
BRENZAVVY may increase the risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. Consider lowering the dose of these agents when coadministered with BRENZAVVY.
MOST COMMON ADVERSE REACTIONS (>5%): Female genital mycotic infections, urinary tract infection and increased urination.
USE IN SPECIFIC POPULATIONS
• Pregnancy: BRENZAVVY is not recommended during the second and third trimesters.
• Lactation: BRENZAVVY is not recommended when breastfeeding.
• Geriatric patients: There is a higher incidence of adverse reactions related to volume depletion.
• Renal Impairment: There is a higher incidence of adverse reactions related to reduced renal function.
• Hepatic Impairment: BRENZAVVY is not recommended for patients with severe hepatic impairment.
For additional important safety information about BRENZAVVY, please see the full Prescribing Information.
All trademarks, registered or otherwise, are the property of their respective owner(s).